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Background: Developing inhibitors is a rare event during the treatment of hemophilia A. The 
multifacets and uncertainty surrounding the development of inhibitors further complicate the 
process of estimating inhibitor rate from the limited data. Bayesian statistical modeling provides 
a useful tool in generating, enhancing, and exploring the evidence through incorporating all 
the available information.
Methods: We built our Bayesian analysis using three study cases to estimate the inhibitor 
rates of patients with hemophilia A in three different scenarios: Case 1, a single cohort of 
previously treated patients (PTPs) or previously untreated patients; Case 2, a meta-analysis of 
PTP cohorts; and Case 3, a previously unexplored patient population – patients with baseline 
low-titer inhibitor or history of inhibitor development. The data used in this study were extracted 
from three published ADVATE (antihemophilic factor [recombinant] is a product of Baxter for 
treating hemophilia A) post-authorization surveillance studies. Noninformative and informa-
tive priors were applied to Bayesian standard (Case 1) or random-effects (Case 2 and Case 3) 
logistic models. Bayesian probabilities of satisfying three meaningful thresholds of the risk of 
developing a clinical significant inhibitor (10/100, 5/100 [high rates], and 1/86 [the Food and 
Drug Administration mandated cutoff rate in PTPs]) were calculated. The effect of discounting 
prior information or scaling up the study data was evaluated.
Results: Results based on noninformative priors were similar to the classical approach. Using 
priors from PTPs lowered the point estimate and narrowed the 95% credible intervals (Case 1: 
from 1.3 [0.5, 2.7] to 0.8 [0.5, 1.1]; Case 2: from 1.9 [0.6, 6.0] to 0.8 [0.5, 1.1]; Case 3: 2.3 
[0.5, 6.8] to 0.7 [0.5, 1.1]). All probabilities of satisfying a threshold of 1/86 were above 0.65. 
Increasing the number of patients by two and ten times substantially narrowed the credible 
intervals for the single cohort study (1.4 [0.7, 2.3] and 1.4 [1.1, 1.8], respectively). Increasing the 
number of studies by two and ten times for the multiple study scenarios (Case 2: 1.9 [0.6, 4.0] 
and 1.9 [1.5, 2.6]; Case 3: 2.4 [0.9, 5.0] and 2.6 [1.9, 3.5], respectively) had a similar effect.
Conclusion: Bayesian approach as a robust, transparent, and reproducible analytic method can 
be efficiently used to estimate the inhibitor rate of hemophilia A in complex clinical settings.
Keywords: inhibitor rate; meta-analysis; multicentric study; Bayesian; hemophilia A
Background
Challenges in estimating the development of inhibitors
The development of inhibitory antibodies, usually IgG 4, is a natural response of the 
host immune system to exogenous factor VIII in patients with hemophilia, who are 
devoid of endogenous factor VIII and therefore not naturally tolerant to it. Some forms 
of immunological reaction are observed in more than half of the patients at the first 
exposure to factor VIII. In many cases, the antibodies are able to block factor VIII 
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clotting activity, and their presence can be detected and quan-
titated using a specific test, the Bethesda assay. Inhibitory 
responses of more than five Bethesda units are called high 
responding antibodies. Approximately one-third of inhibitors 
disappear spontaneously, while others are persistent, making 
exogenous factor VIII ineffective and requiring the use of 
bypassing agents to stop bleeding or prolonged administration 
of high-dose factor VIII to eradicate the inhibitor (immune 
tolerance induction treatment).
Developing inhibitors against factor VIII concentrates 
is the most severe and costly complication of the treatment 
of hemophilia A.1 Patients who develop inhibitors tend 
to have more severe bleeds, either because they are often 
treated on demand more than prophylactically, or because 
their bleeds are more difficult to stop. As to the utilization 
of factor concentrates, this might be lower, when patients are 
preferentially treated with bypassing agents, or higher, when 
low-titer or subclinical inhibitors are treated with factor VIII, 
usually requiring a neutralizing dose (formally calculated 
or empirically determined) in addition to the usual dose of 
concentrates required to prevent bleeding.
There are several reasons that complicate studying the 
determinants of inhibitor development.2 The first is that the 
development of inhibitory antibodies is a combination of 
different events, more than a single one, with nothing as 
simple as black and white.3–6 The second is the uncertainty 
of explaining both known and unknown risk factors associ-
ated with the development of inhibitors.7,8 The third is the 
rarity of the disease, which hampers the opportunity to obtain 
substantial comparative data.2
In this challenging scenario, it is important to determine 
the risk associated with specific brands or classes of factor 
concentrates, because the type of product is one of the few 
actionable risk factors in the field.9,10 Other characteristics 
of the treatment regimen such as dose, frequency, indication, 
and concomitant treatments or exposures also contribute to 
the risk of inhibitor development.11–13 Progress in this field 
requires a close collaboration with complementary expertise. 
Knowledge of immunology and basic science can help gain 
a broader and deeper understanding of the molecular and 
cellular mechanisms driving the development or breach of 
tolerance.14–17 Clinical investigators can work to dissect the 
common characteristics among the heterogeneous clinical 
manifestations of inhibitory responses. Epidemiologists and 
biostatisticians can develop more powerful and efficient ways 
of looking at the available data and generating new ones.
There are several unmet needs in the statistical models used 
to analyze observational data about inhibitor development, 
which relate to the rarity of adverse events in an already rare 
disease.18–24 The first critical issue is the scarcity of evidence, 
which emphasizes the need for incorporating external evi-
dence to increase the power and the informative value of small 
and otherwise weak cohorts.19 A second issue is the need for 
an efficient way to analyze the intricate relationship between 
treatment, time, and the varying risk of events over time.25 A 
third is the need to adjust for covariates (known risk factors) 
when performing multivariable exploration of, for example, 
inhibitor rates in previously untreated patients (PUPs). The 
fourth and last is the proper assessment and comparison of 
event rates generated by nonparallel cohorts.26–28 In the cur-
rent article, we address the first and fourth issues.
A powerful approach to the abovementioned problems 
might be a Bayesian framework. The Bayesian approach to 
interpreting experimental data from a clinical study consists 
of modeling the logical process leading to a change in opinion 
from before to after the availability of new information (the 
evidence provided by a new observation).
The benefit of the Bayesian approach derives from the 
opportunity of making use of existing knowledge in the 
assessment of data that extends to either incorporating that 
knowledge in the final results or using it as a standard to 
quantify the comparison between the new evidence and the 
previous knowledge. That knowledge could be a similar 
measure in a similar unrelated trial, or a threshold of clini-
cal importance.
The concepts behind Bayesian inference
Statistical inference is the process of fitting a probability 
model to a set of observed samples from a population to 
summarize the results by a probability distribution on the 
parameters of interests to make a general statement about 
the population and predictions for new observations. In the 
classical (frequentist) approach, the statistical modeling 
involves only fitting a probability distribution to the observed 
experimental data to model the likelihood of the observed 
experimental data for a given estimate of interest such as 
treatment effect and incidence rate. Unlike the classical 
approach, the Bayesian approach combines experimental 
and prior or external information via the Bayes theorem, to 
produce the posterior distribution that is used to make all 
inferences about the estimate of interest.
 p p pd d| | ( )data  data( ) ∼ ( )× d  (1)
where d is the parameter of interest.
 
Posterior distribution ~ data likelihood
prior distribution×  
 (2)
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As shown in Equations 1 and 2, p(d) represents prior 
distribution of the parameter of interest (henceforth to be 
referred to as “the parameter”), ie, the prior or external 
information about the estimate of treatment effect, incidence 
rate, etc; p(data|d), the likelihood function, specifies the 
statistical model of the observed experimental data given 
the parameter; and p(d|data) is the posterior distribution of 
the parameter, which is essentially a combination of the evi-
dence provided by the observed experimental data and prior 
relevant data from clinical experience or past research evi-
dence.29,30 In many cases, the posterior distribution p(d|data) 
is intractable, and therefore to make inferences about the 
parameter the Bayesian approach uses Monte Carlo Mar-
kov Chain to obtain samples from the posterior p(d|data).31 
Monte Carlo Markov Chain is an iterative process, with 
each iteration yielding a realization or observation from 
the posterior distribution p(d|data). Typically, investigators 
will conduct a large number of iterations or simulations: 
1,000–10,000, or even more. These are used to inform 
posterior inferences about the parameter. For example, the 
posterior mean or median is used to estimate the parameter, 
while the 2.5th and 97.5th observations are used as the 95% 
credible interval (CrI) for the parameter. The probability of 
the point estimate less than a certain threshold is abstained 
by calculating the proportion of the cases lower than the 
threshold over the total number of the interactions. Table 1 
provides a brief summary of the comparison of main features 
of the frequentist and Bayesian approaches in clinical trials. 
The difference between Bayesian and frequentist statistical 
inference is presented in Table 1, and the definitions and 
descriptions of Bayesian terminologies used in this article 
are given in Table 2.
Objectives of this article
By using real clinically observed data from the recently 
published articles,32–34 we aimed to demonstrate the benefits 
or advantages of Bayesian approach in estimating the risk 
of developing inhibitors among patients with hemophilia 
A from the following aspects: increasing the credibility of 
the results and the understanding of the underlying mecha-
nisms by incorporating external evidence; generating prob-
abilities to be used in a physician-to-patient interaction.
Table 1 Brief comparison of the frequentist and Bayesian approaches in clinical trials
Feature Frequentist approach Bayesian approach
Interpretation of probability The proportion of times an event will occur in an 
infinitely long series of repeated identical situations
The “degree of belief” an event (or a number of 
repeatable events) will occur
Main question What is the probability of data (trial result), given 
the hypothesis (treatment effect)?
What is the probability of the hypothesis 
(treatment effect), given the data (trial result)?
Design features Hypotheses, type I and II errors Hypotheses, prior or external information
Reasoning paradigm Deductive reasoning Inductive reasoning 
Trial monitoring Prespecified with adjustments for type I error for 
interim analyses
Adaptive by design based on accumulating evidence
Condition of drawing statistical inference Inference based on observed experimental data Inference based on observed experimental data and 
prior information
Information for 
analysis
Use of external 
information/pre-belief
Informally considered only at study design stage, 
eg, sample size calculation
Formally incorporated in the design, analysis, and 
interpretation as a prior
Experimental data Summarized via the likelihood function, which 
captures all information provided by the 
observed data regarding any unknown population 
parameters
Summarized via the likelihood function, which 
captures all information provided by the 
observed data regarding any unknown population 
parameters
Results summaries Point estimate The “best estimate” obtained from observed 
experimental data 
A weighted point estimate from the posterior 
distribution derived by combining all relevant 
sources of information including the external 
information and observed experimental data
Interval estimates 95% CI: an interval that we are 95% confident 
that the true value of the unknown parameter 
would be as low as its lower bound and as high as 
its upper bound
95% CrI: an interval has a 0.95 probability that the 
unknown parameter would lie within, given the 
observed experimental data
Probabilities P-value, the chance of observing a result as 
extreme as what is seen in the experiment when 
the null hypothesis of no effect is true 
Posterior probabilities
Decision making Framework Not straightforward and hard to apply in clinical 
practice
Intuitive and based on minimizing expected losses; 
easy to apply in clinical practice
Abbreviations: CI, confidence interval; CrI, credible interval.
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Methods
Overall study design
This article is built around three case studies and uses a stan-
dardized multistep approach to show 1) how the Bayesian 
results compare with those based on the commonly used clas-
sical approach; 2) the impact of different sources of external 
information used to construct a Bayesian prior; 3) the use of 
different sources of external information as thresholds against 
which to benchmark Bayesian posterior estimates of risk; and 4) 
the impact of the size of information on the Bayesian posterior 
estimates. In this section, we describe the three case studies, the 
statistical details, and the data source we used for the simulation.
Case study scenarios and patient 
populations
Case 1: analyzing a rare adverse event in a single 
cohort
The first case was set to represent the analysis of a single 
study, where all patients were treated with the same FVIII 
product, aiming to assess the rate of inhibitor development in 
the cohort of patients with hemophilia A including previously 
treated patients (PTPs) and PUPs. For this case, we reanalyzed 
the same cohort already published by Oldenburg et al.32 We 
used this case to explore and discuss the basics of the Bayesian 
approach and the pros and cons of choosing different priors.
Case 2: analyzing a rare adverse event by pooling a 
set of studies in a meta-analysis
The second case was conceived to represent a meta-anal-
ysis of studies assessing the rate of inhibitors in a set of 
 independent but similar studies in comparable populations of 
patients with hemophilia A; for this case, we used an earlier 
article we published.33 The main goal of this case was to show 
how the evidence synthesized from meta-analysis can be 
further enhanced using Bayesian approach by incorporating 
external information through priors.
Case 3: analyzing the inhibitor rate in a previously 
unexplored setting
The third case illustrates how Bayesian method can be used 
to explore a new clinical setting for which no obvious priors 
are available in the literature. Although the study design and 
data collection were similar to the second case, the patient 
population was defined as the patients with low-titer inhibi-
tors at baseline or positive personal history of inhibitors, 
which was definitely different and not directly comparable 
to any existing ones.34 The challenge presented in this case 
was how to properly choose priors to explore an unstudied 
population. In addition to that, the data used in this case were 
extremely sparse in a multicenter/meta-analytical setting, 
where no outcomes were observed in some centers/studies 
(the so-called zero event).
Source data and outcome
The individual data sets used to build our cases for illustra-
tion purposes32–34 were from the ADVATE post-authorization 
safety studies (PASS) program. The study population in 
PASS studies were hemophilia A patients undergoing 
treatment (prophylaxis or on-demand) with ADVATE in 
routine clinical use. The primary safety  outcome in these 
Table 2 Definitions of Bayesian statistical inference
Terms Definition Examples of interpretation
Bayesian statistical 
inference
p(d|data) ∼ p(data|d) × p(d), posterior distribution is the joint 
distribution of prior distribution and the distribution of data 
likelihood
Obtaining the most updated evidence by combining the 
information from the study data with other sources
Prior p(d), the probability distribution of the unknown parameter 
of interest
Preexisting knowledge or evidence, or external information of 
treatment effect or incidence rate
Noninformative prior A prior distribution is called noninformative if the prior has 
little information to impact the posterior distribution
A noninformative prior is also called vague or flat prior
Informative prior A prior is called informative if the prior contains some 
information which impacts the posterior distribution 
The information presented in the prior can be the external 
evidence, pre-believe, or expert opinion
Likelihood function p(data|d), the probability distribution of the data observed 
over the parameter of interest, which embeds the statistical 
model
Data obtained for a study designed to investigate certain 
treatment effects or diseases
Posterior p(d|data), the updated probability distribution of the 
parameter of the interest given data, which is obtained by 
combining data likelihood and prior distribution
Updated evidence after combining the evidence from the 
study data and other information
95% CrI 95% CrI, the estimated interval has a 95% probability 
(credibility) that the parameter of interest lies within it
95% probability is a direct quantity attached to the obtained 
interval of the posterior estimates of the parameter of interest
Abbreviations: CrI, credible Interval; d, parameter of interest.
Journal of Blood Medicine 2016:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
243
Bayesian approach in estimating inhibitor rate
studies is defined as inhibitor levels during the study period 
including de novo, recurrent, and persistent inhibitors. We 
adopted the cutoffs of inhibitor classification specified 
in the original PASS protocols: 1.0 Bethesda unit (BU) 
for US, EU, and Australian PASS; and 0.6 BU for Japan, 
Italian, Korean, and Taiwan PASS (studies adopting the 
Nijmegen modification).32,33 More detailed description of 
the data such as hemophilia severity and FVIII exposure 
history and the case-specific definitions of inhibitors are 
presented in Table 3.
Setting basic models with noninformative 
priors
For all the three cases, Bayesian statistical models with non-
informative priors were introduced first as the basic starting 
model. For Case 1, classical logistic and Bayesian logistic 
models were used. For Case 2 and Case 3, classical random-
effects logistic and Bayesian hierarchical random-effects 
logistic models were adopted, through which the patients 
from the same study were treated as within the same cluster. 
The random-effects model was adopted as the most common 
choice for individual patient data (IPD) meta-analyses. As 
for noninformative prior for log odds, the normal distribution 
with mean equals to zero (equal odds between developing 
or not developing inhibitor) and precision equals to 0.00001 
were specified. The uniform distribution was used to specify 
the prior for the between-study standard deviation in the 
random-effects logistic model. The details of prior specifica-
tions are presented in Table S1.
Choosing informative priors
As a second step, we replaced noninformative priors with 
information-rich priors to incorporate the preexisting 
external information or knowledge from earlier studies 
into the analysis of the current study data. Unlike nonin-
formative priors, informative ones contribute information 
to the posterior estimates, which can be looked at as a 
“combination” of the preexisting evidence with evidence 
generated by the current experiment. To this scope, we 
sought relevant comparable priors and tested two different 
sets of informative priors. The first set 1) comprised the data 
obtained during the treatment with a certain molecule (eg, 
rAHF-PFM) in different studies; specifically i) estimates of 
inhibitor rates from the manufacturer’s pivotal studies35; ii) 
estimates of inhibitor rates from a meta-analysis36; and iii) 
estimates of inhibitor rates from an independent prospec-
tive multicentric cohort.37 The second set of informative 
priors 2) comprised pooled inhibitor rates for any FVIII 
concentrate, including: i) a meta-analysis36 and ii) an inde-
pendent prospective multicenter cohort.37 The details of 
generating informative priors, published data, are  presented 
in Table S1.
In this study, Case 3 was specifically chosen not to have a 
study on the same patient population already available; thus, 
no obvious informative priors can be located in the literature. 
Notwithstanding, we wanted to show the value of the Bayes-
ian approach in exploring how the rate of inhibitor develop-
ment in this population would change when the known rate in 
PTPs and that in PUPs is added in. Consequently, in addition 
Table 3 Information of study data and outcome
Study information Case 1 (n=428) Case 2 (n=1,188) Case 3 (n=219)
Patient population PTP and PUP, all severity PTP and PUP, moderate-to-severe 
patients
Patients with baseline low-titer inhibitor or 
history of inhibitor
Source of PASS data Europe Australia
Europe
Italy
Japan
The USA
Australia
Europe
Italy
Japan
The USA
Taiwan
South Korea
Hemophilia severity
Severe, n (%)
308 (72.0) 883 (74.3) 198 (90)
FVIII exposure history
>50 EDs, n (%)
393 (91.8) 1089 (91.6) 214 (97.7)
Defined outcome: developing 
inhibitora, n (%)
6 (1.4) 21 (1.8) 6 (2.7)
Notes: aInhibitor defined in Case 1: inhibitor >1.0 BU; inhibitor defined in Case 2: de novo, recurrent, or persistent inhibitor; inhibitor defined in Case 3: titer increase or 
inhibitor recurrence. De novo inhibitor was defined as inhibitor occurring in patient with negative history of inhibitors and with negative titer at baseline; recurrent inhibitor 
was defined as the inhibitor observed for the patient with a history of inhibitor; persistent inhibitor was defined as the inhibitor that was present at the beginning of the study 
and carried through during the study.
Abbreviations: BU, Bethesda unit; ED, exposure day; PASS, post-authorization safety studies; PTP, previously treated patient; PUP, previously untreated patient.
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to the informative priors used in the first two cases, we also 
added the inhibitor rates for PUPs reported in the European 
Hemophilia Safety Surveillance (EUHASS) study37 for 1) the 
specific molecule and for 2) all products. The key rationale 
was to assess the robustness or sensitivity of the posterior 
inhibitor rates seen when a prior based on a truly high-risk 
population is used, ie, the worst-case scenarios. The details 
of generating priors for Case 3 are presented in  Table S1.
Calculating probabilities
To make this more evident and show another peculiar prop-
erty of the Bayesian framework, we further calculated, for 
the third case, the Bayesian probabilities of the posterior 
inhibitor rates being lower than three specific clinically 
meaningful thresholds, two high rates (10/100 and 5/100)38 
recommended by International Society on Thrombosis and 
Haemostasis (ISTH), and the US Food and Drug Adminis-
tration (FDA)-mandated cutoff rate in PTPs (1/86).39,40 The 
probability was calculated as the cumulated proportion of the 
posterior inhibitor rate less than the threshold over the total 
number of iterations, ie, the number of resamplings used in 
each Bayesian model.
Weighting prior information
We then moved to show the effect of scaling down or dis-
counting the value of the prior information in Case 3, for 
which due to the inability to use a full consistent informative 
prior, one might want to assign less weight to the informa-
tion carried by the selected priors. The weight of the prior 
was reduced in the following ways: 1) by decreasing the 
precision, ie, enlarging the variance of the priors depending 
on how relevant the particular piece of information is to the 
study we are assessing.30,41 In our third case, we discount the 
precision of the rates of inhibitor in PUPs in EUHASS for 
the specific molecule and for any factor VIII concentrate 
by 75% and 95% each, respectively. This is equal to the 
human process of any perceived information: “you told 
me that the rate of event is this, but I only 25% trust your 
information”; and 2) a second approach to obtain the same 
objective, ie, to undervalue the contribution of the priors, 
is scaling up the weight of the study data by increasing the 
precision assigned to the experimental data. One easy and 
understandable way to do this is to simulate the impact on 
posterior estimates of increasing the study sample size. 
Thus, we showed the effect of increasing the study data 
sample size by two and ten times for all three study cases. 
The increment of sample was performed in two ways: 1) 
for all the three cases, increasing the number of events and 
number of patients in each center proportionally, ie, mul-
tiplying the numbers of events and patients for each center 
by two or ten times; and 2) for Cases 2 and 3, increasing 
the numbers of centers by two or ten times while keeping 
the numbers of events and patients in each center as the 
same as in the original data. We reran the Bayesian model 
with noninformative priors using the purposely inflated 
data for all the three cases to test the idea and then further 
reanalyzed the effect of data inflation for Case 3 with all 
informative priors previously used.
Analysis and reporting
Throughout this study, posterior inhibitor rates (our results) 
were reported as percentage rates with 95% associated con-
fidence interval (CI) in the case of classic statistics, or 95% 
CrI in the case of Bayesian statistics. Graphic, descriptive 
statistics and classical meta-analyses were performed using 
STATA 13.1 (StataCorp LP, College Station, TX, USA). 
Bayesian analyses were performed using WinBUGS soft-
ware 1.4.3 (http://www.mrc-bsu.cam.ac.uk/bugs/). In every 
Bayesian analysis, two chains were run simultaneously, and 
the convergence of the Bayesian models was assessed based 
on the history trace, posterior density, and autocorrelation 
plots for parameters of interest. The codes of Bayesian models 
that detailed setups on the Bayesian simulations are presented 
in the  Table S2.
Results
Raw inhibitor rates in three cases
For Case 1, six inhibitors (1.4%) were reported among 428 
patients. For Case 2, five studies were included in the IPD 
meta-analysis, and 21 inhibitors (1.8%) were reported in 
1,188 patients. For Case 3, IPD were extracted from seven 
PASS, and six inhibitors (2.7) were reported in 219 patients 
(Table 4).
Comparing results from Bayesian 
approach to classical approach
As expected, the results obtained from classical analytical 
approach and Bayesian statistical model using noninforma-
tive priors were similar for all the three cases. For the single 
cohort study (Case 1), the estimates were the same to one 
decimal place (percent rate [95% CI]: 1.3% [0.5, 2.7]; percent 
rate [95% CrI]: 1.3% [0.5, 2.7]). For the pooled analysis (Case 
2), the Bayesian posterior estimates gave a slightly wider 95% 
CrI (1.9% [0.8, 4.5]) toward the lower end as compared to the 
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estimate from the classical approach (1.9% [0.8, 4.5]). For the 
cohort of patients with previous/current inhibitor (Case 3), 
the posterior estimates from the Bayesian model showed a 
slightly lower percent rate and wider 95% CrI (2.3% [0.5, 
6.8]) as compared to the estimate from classical approach 
(2.6% [1.0, 6.8]; Table 4, Figure 1A–C).
Impact of using informative priors in 
Bayesian analysis
For Case 1 and 2, using external information as priors con-
sistently narrowed the CrIs and lowered the central estimate 
of percentage rates. The range of the inhibitor percentage 
rates for the single cohort (Case 1) was 0.8%–1.3% and 
for the pooled analysis was 0.8%–1.9%. For the cohort 
of patients with previous/current inhibitor (Case 3), the 
posterior estimates of inhibitor percentage rates changed 
depending on the external information brought in by pri-
ors. The lowest percentage rates with narrowest 95% CrI 
was obtained using the informative prior generated from 
the EUHASS study of PTPs for all FVIII products: 0.7% 
(0.5, 1.1). The highest percentage rate was gained using the 
informative priors generated from the EUHASS study of 
PUPs for all FVIII products: 24.9% (21.1, 29.2; Table 4, 
Figure 1A–C).
Comparing posterior inhibitor rates to 
thresholds
For the cohort of patients with previous/current inhibitor 
(Case 3), the posterior estimates of inhibitor rates were 
compared to the selected thresholds, and the probabilities 
of posterior inhibitor rates lower than the thresholds were 
then calculated. A probability of 1 means that the calcu-
lated rate of inhibitors is certainly below the threshold, 
and a probability of 0.5 means a 50% likelihood that the 
rate is below the threshold. Testing a threshold for the rate 
of inhibitors of 10%, six out of eight comparisons (when 
noninformative prior and informative priors were generated 
from the studies of PTPs) showed a probability >0.99. In 
contrast, when the EUHASS PUP study results were used 
as priors, the probabilities of a rate lower than 10% dropped 
dramatically to <0.001. Similar findings were obtained 
when the threshold was dropped to lower than 5%. When 
Table 4 Inhibitor rate (on percentage scale) for three different cases
Approaches and priors Case 1 Case 2 Case 3
Method Single study Meta-analysis Multicenter cohort – no 
appropriate priors
Test data (number of inhibitors/number of patients) PASS data30 (6/428) PASS data31 (21/1,188) PASS data32 (6/219)
Classical statistical analysis: percent rate (95% CI) 1.3 (0.5, 2.7) 1.9 (0.8, 4.5) 2.6 (1.0, 6.8)
Bayesian statistical analysis: percent rate (95% CrI)
Non-informative prior 1.3 (0.5, 2.7) 1.9 (0.6, 6.0) 2.3 (0.5, 6.8)
Informative prior: Baxter pivot study (1/102) 1.3 (0.5, 2.5) 1.6 (0.6, 4.1) 1.8 (0.5, 4.8)
Informative prior: meta-analysis of OS (seven ADVATE studies; 3/569) 0.9 (0.4, 1.9) 1.0 (0.4, 2.2) 0.9 (0.3, 2.3)
Informative prior: meta-analysis of OS (38/3,866) 1.0 (0.8, 1.4) 1.0 (0.8, 1.4) 1.0 (0.8, 1.4)
Informative prior: EUHASS study of de novo inhibitor in PUPs, ADVATE 
(37/141)
N/A N/A 23.4 (17.5, 30.7)
Informative prior: EUHASS study of de novo inhibitor in PUPs (108/417) N/A N/A 24.9 (21.1, 29.2)
Informative prior: EUHASS study of inhibitors in PTPs, ADVATE (5/707) 1.0 (0.5, 1.8) 1.1 (0.5, 2.1) 1.0 (0.4, 2.1)
Informative prior: EUHASS study of inhibitors in PTPs (all FVIII) (26/3,736) 0.8 (0.5, 1.1) 0.8 (0.5, 1.1) 0.7 (0.5, 1.1)
Discounted prior: discounting EUHASS in PUPs, ADVATE by 75% N/A N/A 16.9 (9.0, 29.4)
Discounted prior: discounting EUHASS in PUPs, ADVATE by 95% N/A N/A 5.3 (2.2, 16.0)
Discounted prior: discounting EUHASS in PUPs, all by 75% N/A N/A 22.2 (15.7, 30.4)
Discounted prior: discounting EUHASS in PUPs, all by 95% N/A N/A 12.3 (5.4, 25.8)
Enhanced data: enhancing study data by two times – increasing number of 
patients (with noninformative prior)
1.4 (0.7, 2.3) 2.0 (0.6, 6.4) 2.2 (0.5, 6.6)
Enhanced data: enhancing study data by two times – increasing number of 
studies (with noninformative prior)
N/A 1.9 (0.9, 4.0) 2.4 (0.9, 5.0)
Enhanced data: enhancing study data by ten times – increasing number of 
patients (with noninformative prior)
1.4 (1.1, 1.8) 2.1 (0.6, 6.6) 1.6 (0.4, 5.4)
Enhanced data: enhancing study data by ten times  – increasing number of 
studies (with noninformative prior)
N/A 1.9 (1.5, 2.6) 2.6 (1.9, 3.5)
Abbreviations: CI, confidence interval; CrI, credible interval; EUHASS, European Hemophilia Safety Surveillance; OS, observational study; PASS, post-authorization safety 
studies; PTP, previously treated patient; PUP, previously untreated patient; N/A, not applicable.
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Figure 1 Estimates of inhibitor rate obtained using classical or Bayesian approaches for three study cases A, B, C respectively.
Abbreviations: CI, confidence interval; CrI, credible interval; EUHASS, European Hemophilia Safety Surveillance; MA, meta-analysis; OS, observational study; PTP, previously 
treated patient; PUP, previously untreated patient.
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the threshold was dropped further to the FDA-approved 
rate for PTPs of 1/86, only the probability using priors 
for the EUHASS study in PTPs for all products was >0.9, 
but all estimations using PTPs as priors were still above 
0.65 (Table 5).
Impact of sample size of data
We found that increasing the number of patients narrowed the 
CrI for Case 1 (ie, the mimic of single-center studies), but 
had little impact on the posterior estimates of Cases 2 and 
3, which represented multicenter study settings. However, 
when more centers were added to get the same sample size, 
the CrIs noticeably narrowed. Another interesting observa-
tion is that when the number of patients was increased in 
each center while the number of centers remained the same, 
the posterior inhibitor rates decreased for Case 3, in which 
three of seven centers reported no inhibitor event in the 
original data (Table 3; more exploratory results are found 
in Table S2).
Discussion
In this study, we used three cases from the real-world data to 
examine the abilities of the Bayesian approach in analyzing 
and interpreting rare events observed in a rare population. 
In comparison of the frequentist (or classical) approach, the 
advantages of Bayesian framework majorly lay on the fol-
lowing three points.
First, unlike the classical frequentist statistics, Bayesian 
approach provides a way to dynamically update the evidence 
around a certain event using all the available information. In 
fact, posterior estimates are weighted averages based on prior 
and current experimental evidence/data, with the weights 
determined by the precision of the corresponding evidence. 
As in our study cases, we updated the estimate of the inhibi-
tor rate that is represented by the posterior distribution by 
combining the information on the inhibitor rate contained in 
our data and the knowledge on the inhibitor rate found in the 
external study. This nature leads to the continuous updates 
of the evidence upon the availability of new data. The most 
informative example of using the Bayesian framework is 
where the inhibitor rate among patients with low-titer inhibi-
tor at baseline or personal history of the inhibitor had been 
given little consideration to date. Therefore, comparing the 
posterior estimates of the inhibitor rate obtained from the 
study data commonly used as clinical thresholds will provide 
clinicians with meaningful ways to interpret the results.
Second, the Bayesian posterior probability is funda-
mentally different from the P-value used for frequentist 
hypothesis test. For instance, when testing “the inhibitor 
rate (in our population) is <10%” in our case, the P obtained 
Table 5 Probabilities calculated for the inhibitor rates lower than specific thresholds for Case 3
Prior Case 3: PASS Threshold 1 Threshold 2 Threshold 3
Bayesian statistical analysis: percent rate (95% CrI) Multicenter study – no 
appropriate priors
<10/100 <5/100 <1/86
Noninformative prior 2.3 (0.5, 6.8) 0.994 0.921 0.165
Informative prior: Baxter pivot study (1/102) 1.8 (0.5, 4.8) >0.999 0.979 0.225
Informative prior: meta-analysis of OS (seven ADVATE studies) (3/569) 0.9 (0.3, 2.3) >0.999 >0.999 0.677
Informative prior: meta-analysis of OS (38/3,866) 1.0 (0.8, 1.4) >0.999 >0.999 0.782
Informative prior: EUHASS study of de novo inhibitor in PUPs, ADVATE 
(37/141)
23.4 (17.5, 30.7) <0.001 <0.001 <0.001
Informative prior: EUHASS study of de novo inhibitor in PUPs (108/417) 24.9 (21.1, 29.2) <0.001 <0.001 <0.001
Informative prior: EUHASS study of inhibitors in PTPs, ADVATE (5/707) 1.0 (0.4, 2.1) >0.999 >0.999 0.658
Informative prior: EUHASS study of inhibitors in PTPs (all FVIII) (26/3,736) 0.7 (0.5, 1.1) >0.999 >0.999 0.988
Discounted prior: discounting EUHASS in PUPs, ADVATE by 75% 16.9 (9.0, 29.4) 0.051 <0.001 <0.001
Discounted prior: discounting EUHASS in PUPs, ADVATE by 95% 5.3 (2.2, 16.0) 0.876 0.449 0.001
Discounted prior: discounting EUHASS in PUPs, all by 75% 22.2 (15.7, 30.4) <0.001 <0.001 <0.001
Discounted prior: discounting EUHASS in PUPs, all by 95% 12.3 (5.4, 25.8) 0.306 0.016 <0.001
Enhanced data: enhancing study data by two times – increasing number of 
patients (with noninformative prior)
2.2 (0.5, 6.6) 0.995 0.932 0.161
Enhanced data: enhancing study data by two times – increasing number of 
studies (with noninformative prior)
2.4 (0.9, 5.0) 0.998 0.967 0.305
Enhanced data: enhancing study data by ten times – increasing number of 
patients (with noninformative prior)
1.6 (0.4, 5.4) 0.998 0.976 0.067
Enhanced data: enhancing study data by ten times – increasing number of 
studies (with noninformative prior)
2.6 (1.9, 3.5) >0.999 >0.999 <0.001
Abbreviations: CI, confidence interval; CrI, credible interval; EUHASS, European Hemophilia Safety Surveillance; OS, observational study; PASS, post-authorization safety 
studies; PTP, previously treated patient; PUP, previously untreated patient.
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from the frequentist test tells us the probability of wrongly 
rejecting the null hypothesis – “the inhibitor rate equals to 
10%” in our case. This P-value reflects the type I error. In 
addition, thus the statistically significance from frequentist 
approach is built on an arbitrary cutoff for tolerating this 
type I error, say 0.05.42 In our example, if the “probability” 
of “the inhibitor rate is ≥10%” is <0.05, we conclude that this 
hypothesis can be rejected. However, this probability is not 
in fact a probability directly related to the acceptance of the 
testing hypothesis, but a level of confidence that the chance of 
mistakenly rejecting the null hypothesis is low. In fact, when 
P<0.05, we can reject the null hypothesis, but we are never 
able to say that the probability of “the inhibitor rate being 
<10%” is truly 0.95. On the other hand, the Bayesian prob-
ability is a quantity of the testing hypothesis, ie, the “degree 
of truth” of the study hypothesis. The Bayesian can really 
test the probability that the rate of inhibitor in our sample 
is <10%. If P=0.95, we are confident that the probability of 
“the inhibitor rate being <10%” is actually 0.95.
Third point is the different interpretations between the 
CI in classical approach and CrI in Bayesian approach. Back 
to our example, the 95% CI is interpreted as “the estimates 
of the inhibitor rate will fall in between these two boundar-
ies 95% of the time if the data can be repeated infinitely”. 
It cannot be used to make an assertion about the current 
test based on a single sample set without the assumption of 
the infinite repetition. In comparison, the 95% CrI tells us 
a straightforward story, “given the data and the model, the 
chance of the true inhibitor rate fall in this interval is 95%”.
Some further considerations are hopefully of value. For 
Cases 1 and 2, the Bayesian models with noninformative 
priors yielded results comparable to the classical approach. 
For third study case, the point estimate of inhibitor rate 
obtained from the Bayesian random-effects logistic model 
was lower than that obtained from the classical random-
effects logistic model. The reason is that the data used for 
this example are extremely sparse. In three out of seven 
pooled studies, there were no inhibitors observed. The clas-
sical logistic model directly takes event as outcome and thus 
fails to generate the estimates when no event is in the data. 
Therefore, when classical random-effect logistic was used 
to pool the data from seven individual studies, the three 
studies without outcomes were ignored, and the inhibitor 
rate was estimated from the four studies with observed 
inhibitor. Unlike the classical model, the Bayesian model 
resamples the data for certain times (eg, 100,000) based 
on the information provided by the current data and then 
generates the estimates in accordance before  reporting the 
posterior estimates, which usually are the median of the 
entire estimates. In our example, when data reported no 
event, the Bayesian model resampled the data using the 
probability of event sampled around zero. By doing so, 
the Bayesian model was able to incorporate those studies 
reporting no inhibitor into the posterior estimates and thus 
gave a lower inhibitor rate. On the other hand, for the same 
example, the 95% CrIs were wider than the 95% CIs. This 
is because the Bayesian model introduced more random 
uncertainty through noninformative priors that had very 
large variance. When the study data are not large enough, 
random uncertainty will be added in the posterior estimates. 
In our example, we had seven studies that were not even 
able to provide saturated information for estimating the 
between-study variance. Therefore, the model borrowed 
information from noninformative priors that only added 
uncertainty to estimate the between-study variance.
The Bayesian approach provides a very useful tool for 
exploring our Case 3 data, which presents the unexplored 
patient population with no existing evidence. We modeled 
the effect of observing six inhibitors in ∼200 patients from 
the unlikely expectation that the inhibitor rate would have 
been as in Research Of Determinants of INhibitor (RODIN) 
study11, to the optimistic expectation that the rate would have 
not been different from that in PTPs. We also showed how we 
could model the “strength” of this belief, by “discounting” 
the previous information. Critics of the Bayesian approach 
would certainly say that by adding “discounts” you may play 
with data until you show what you want. We would object that 
this would be the case if you were only using one set of priors 
(maybe even discounted). If you instead show the results 
produced by using a whole range of priors, you explore the 
relevance of your previous beliefs and assumptions. Along 
the same lines, we found that Bayesian modeling can be used 
to simulate the effect by increasing the number of patients 
in the same centers or by increasing the number of centers. 
The information found through thes attempts can be easily 
used on estimating the sample size for the future studies. 
All of this richness of information is completely unavailable 
when using the frequentist approach. The reader needs to be 
aware, at this point, that most of the modeling of the impact 
of health care interventions on economics of health care 
systems or quality of life of patient population is generally 
obtained via Monte Carlo chain simulations which are, in 
essence, Bayesian probability applications.30,43
Bayesian estimates can be used to inform clinical deci-
sions in patient management in complex clinical settings. 
The success of integrating all relevant evidence through a 
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Bayesian approach depends on two aspects: 1) how to properly 
choose the clinically relevant priors, and 2) how to statistically 
formulate the clinical knowledge. These tasks need the joint 
force of clinicians and statisticians. Properly implementing the 
Bayesian results in the clinical decision making depends on the 
comprehensive understanding of the evidence, in particular, 
for the findings obtained from the first-time-ever exploration 
regarding new study settings or populations.
In regard to the purpose of serving as case studies for 
conducting Bayesian analysis in hematology area to analyze 
and generate evidence for rare events among rare study 
populations, we chose to use Bayesian random-effect logistic 
regression throughout the entire project for three scenarios for 
simplicity. We are aware that other statistical models such as 
random-effect Poisson regress may be a better choice for rare 
event data with zero outcomes. It is worth noting that properly 
setting up priors can be challenging because it depends on 
the types of outcomes and Bayesian models.
To come back to the clinical ground, we showed how 
the Bayesian posterior distribution can be interrogated to 
get, for example, the posterior probability that the rate of 
inhibitors in a population like the one we studied (eg, patients 
with previous history of inhibitors) was above or below a 
given (clinically meaningful) threshold. This is what, in our 
opinion, is needed for clinical decisions, and, indirectly, for 
policy-making decisions like taking into account the 30% of 
patients with a previous history of developing inhibitors in the 
proportion of population to be suitable to switch concentrate 
as a result of a tender process.
Conclusion
The Bayesian estimates of the inhibitor rate of patients under-
going treatment with ADVATE provide a broader understand-
ing for the clinicians, which can be utilized to inform clinical 
decisions in the management of patients with hemophilia A. 
Bayesian approach as a robust, transparent, and reproducible 
analytic method can be efficiently used to answer the complex 
clinical questions through updating, enhancing, and exploring 
the evidence by incorporating all the available information. 
Furthermore, the Bayesian probability can be directly used by 
clinicians to quantify individual patient’s risk on developing 
certain conditions.
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Supplementary materials
Figure S1 Bayesian codes
Number of updates, 300,000; number of chains, 2; number of thin, 5; burn in, 10,000; seed, 314,159.
Model 1: Simple logistic regression
model {
  r ∼ dbin(p, n)
 logit(p) <- mu #log odds
 mu ∼ dnorm(0, 1.0E-5) # non-informative
  #mu ∼ dnorm (-4.615, 0.990) # PIVOT 1/102, log_odds=log(1/101), var=1/1+1/101
  #mu ∼ dnorm (-5.24, 2.984) # Meta-OS ADVATE, 3/569
  #mu ∼ dnorm (-4.613, 37.626) # Meta-OS ADVATE, 38/3866
  #mu ∼ dnorm (-4.944, 4.965) # EUHASS PTP ADVATE, 5/707
  #mu ∼ dnorm (-4.961, 25.819) # EUHASS PTP ALL, 26/3736
 odds<-exp(mu)
 prop<-odds/(1+odds)
 perc<-prop*100
  }
Note: “number of thin” is a term of Bayesian analysis, which means every 1 sample taking into account over certain 
numbers of samples generated.
Model 2: Random-effects logistic model
model {
 for( i in 1 : Num ) {
  r[i] ∼ dbin(p[i], n[i])
  logit(p[i]) <- mu[i] #log odds
  mu[i] ∼ dnorm(d, tau)
      } 
 d ∼ dnorm(0,1.0E-5) # Non-informative prior 
 # Prior1: Baxter Pivot Trial, 1/102
  #d ∼ dnorm(-4.62,0.99) # log_odds, variance=1/1+1/(102-1), precision=1/var
  #d ∼ dnorm (-5.24, 2.984) # Meta-OS ADVATE, 3/569
  #d ∼ dnorm (-4.613, 37.626) # Meta-OS ADVATE, 38/3866
  #d ∼ dnorm (-1.033, 27.291) # EUHASS PUP ADVATE, 37/141
  #d ∼ dnorm (-1.051,80.029) # EUHASS PUP ALL, 108/417
  #d ∼ dnorm (-4.944, 4.965) # EUHASS PTP ADVATE, 5/707
  #d ∼ dnorm (-4.961, 25.819) # EUHASS PTP ALL, 26/3736
  #d ∼ dnorm (-1.033, 6.822) # EUHASS PUP ADVATE(-75%), 9.25/35.25
  #d ∼ dnorm (-1.033, 1.365) # EUHASS PUP ADVATE(-95%), 1.85/7.05
  #d ∼ dnorm (-1.051, 20.007) # EUHASS PUP ALL(-75%), 27/104.25
  #d ∼ dnorm (-1.052, 4.001) # EUHASS PUP ALL(-95%), 5.4/20.85
 tau<-1/(sigma*sigma)
  sigma∼dunif(0,2) # between study variance is estimated from PASS1
 odds<-exp(d)
 prop <- exp(d)/(1+exp(d)) 
 perc<-prop*100
 ppos1<-step(10/100-prop) 
 ppos2<-step(5/100-prop)
 ppos3<-step(1/86-prop)
    }
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Table S1 Analysis methods and the choice of priors
Approaches and priors Case 1 Case 2 Case 3
Method Single study Meta-analysis Multicentric cohort – no 
appropriate priors
Test data PASS data1 (6/428) PASS data2 (21/1,188) PASS data3 (6/219)
Classical statistical analysis Logistic model Random-effects logistic model Random-effects logistic model
Bayesian statistical analysis Logistic model Hierarchical (random-effects) logistic 
model
Hierarchical (random-effects) 
logistic model
Noninformative prior Ok Ok Ok
Informative prior: Baxter pivotal study (1/102) Ok Ok Ok
Informative prior: meta-analysis of OS (seven ADVATE 
studies) (3/569)
Ok Ok Ok
Informative prior: meta-analysis of OS (38/3,866): do you 
need data per study?
Ok Ok Ok
Informative prior: EUHASS study of de novo inhibitor in 
PUPs, ADVATE (37/141)
No No Ok
Informative prior: EUHASS study of de novo inhibitor in 
PUPs (108/417) 
No No Ok
Informative prior: EUHASS study of inhibitors in PTPs, 
ADVATE (5/707)
Ok Ok Ok
Informative prior: EUHASS study of inhibitors in PTPs (all 
FVIII) 22/3,736
Ok Ok Ok
Discounted prior: discounting EUHASS in PUPs, ADVATE 
by 75%
No No Ok
Discounted prior: discounting EUHASS in PUPs, ADVATE 
by 95%
No No Ok
Discounted prior: discounting EUHASS in PUPs, all by 75% No No Ok
Discounted prior: discounting EUHASS in PUPs, all by 95% No No Ok
Enhanced data: enhancing study data by two times – 
increasing number of patients
Ok Ok Ok
Enhanced data: enhancing study data by two times – 
increasing number of studies
No Ok Ok
Enhanced data: enhancing study data by ten times – 
increasing number of studies
Ok Ok Ok
Enhanced data: enhancing study data by ten times – 
increasing number of studies
No Ok Ok
Note: “OK” means it is valid choice thus will be used in the analysis. “No” means it is no a valid choice and won’t be used in the analysis.
Abbreviations: CI, confidence interval; CrI, credible interval; EUHASS, European Hemophilia Safety Surveillance; OS, observational study; PASS, post-authorization safety 
studies; PTP, previously treated patient; PUP, previously untreated patient.
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Table S2 Assessing the impact of sample size change and choice of priors on the Bayesian posterior estimates
Original data Increasing sample size by two times Increasing sample size by ten times
Test data (number of inhibitors/number 
of patients); number of centers
Case 3: PASS 
(6/219)3; 7 
Increasing number 
of patients in each 
center: (12/438); 7
Increasing number of 
centers: (12/438); 14
Increasing number of 
patients in each center: 
(60/2,190); 7
Increasing number of 
centers: (60/2,190): 70
Noninformative prior 2.3 (0.5, 6.8) 2.2 (0.5, 6.6) 2.4 (0.9, 5.0) 1.6 (0.4, 5.4) 2.6 (1.9, 3.5)
Informative prior: Baxter pivotal study 
(1/102) 
1.8 (0.5, 4.8) 1.8 (0.5, 4.6) 2.1 (0.8, 4.2) 1.4 (0.4, 3.9) 2.6 (1.8, 3.4)
Informative prior: meta-analysis of OS 
(seven ADVATE studies) (3/569)
0.9 (0.3, 2.3) 0.9 (0.3, 2.4) 1.3 (0.5, 2.7) 0.8 (0.3, 2.0) 2.3 (1.5, 3.1)
Informative prior: meta-analysis of OS 
(38/3,866)
1.0 (0.8, 1.4) 1.0 (0.8, 1.4) 1.1 (0.8, 1.5) 1.0 (0.7, 1.4) 1.4 (1.0, 1.8)
Informative prior: EUHASS study of 
de novo inhibitor in PUPs, ADVATE 
(37/141)
23.4 (17.5, 30.7) 23.2 (17.3, 30.4) 21.4 (15.6, 28.1) 22.8 (17.0, 29.8) 11.2 (7.7, 15.4)
Informative prior: EUHASS study of 
de novo inhibitor in PUPs (108/417) 
24.9 (21.1, 29.2) 24.8 (20.1, 29.1) 24.1 (20.4, 28.3) 24.7 (20.8, 28.9) 19.2 (16.1, 22.5)
Informative prior: EUHASS study of 
inhibitors in PTPs, ADVATE (5/707)
1.0 (0.4, 2.1) 1.0 (0.4, 2.1) 1.2 (0.6, 2.4) 0.9 (0.4, 1.9) 2.3 (1.5, 3.0)
Informative prior: EUHASS study of 
inhibitors in PTPs (all FVIII) (26/3,736)
0.7 (0.5, 1.1) 0.8 (0.5, 1.1) 0.8 (0.5, 1.2) 0.7 (0.5, 1.1) 1.2 (0.8, 1.7)
Note: Data presented as percent rate (95% CrI).
Abbreviations: CI, confidence interval; CrI, credible interval; EUHASS, European Haemophilia Safety Surveillance; OS, observational study; PASS, post-authorization safety 
studies; PTP, previously treated patient; PUP, previously untreated patient.
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